

Reference:	FOI.17718.25
Subject:	Myelofibrosis treatments
Date of Request:	7 July 2025

Requested:

1. Please provide the total number of patients treated in the last 6 months for:
 - Polycythaemia Vera (ICD10 code D45)
 - Myelofibrosis (ICD10 code D47.4)
 - Myelofibrosis (ICD10 code D47.4) patients aged 65 and older

2. How many patients were treated in the past 6 months (for any disease) with:
 - Ruxolitinib
 - Fedratinib
 - Momelotinib

3. How many patients were treated with Ruxolitinib in the past 6 months for the following diseases?
 - Myelofibrosis (ICD10 code D47.4)
 - Polycythaemia Vera (ICD10 code D45)
 - Other/Unknown

4. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?
 - a. Of these patients, how many were treated in the past 6 months with Hydroxycarbamide?
 - b. Of these patients, how many were treated in the past 6 months with Interferon therapy?
 - c. Of these patients, how many have received no active treatment in the past 6 months?

5. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.

Response:

Where stated or where the figures in the tables below have been replaced with an asterisk (*), Hywel Dda University Health Board (UHB) is unable to provide you with the exact number of patients due to the low number of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

1. The UHB provides within the table below, the number of patients treated for the listed conditions, and the number treated for Myelofibrosis aged sixty-five (65) and over, during the period 1 January to 30 June 2025.

Condition	Number
Polycythaemia Vera (ICD10 code D45)	84
Myelofibrosis (ICD10 code D47.4)	17
Myelofibrosis (ICD10 code D47.4) patients aged 65 and over	15

2. The UHB provides within the table below, the number of patients treated with the listed medications, for any disease, during the period 1 January to 30 June 2025.

Medication	Number
Ruxolitinib	14
Fedratinib	0
Momelotinib	*

3. The UHB provides within the table below, the number of patients treated with Ruxolitinib for the listed conditions, during the period 1 January to 30 June 2025.

Medication	Number
Myelofibrosis (ICD10 code D47.4)	*
Polycythaemia Vera (ICD10 code D45)	*
Other/Unknown	10

4. The UHB confirms that one hundred and thirty-four (134) patients were diagnosed with Myelofibrosis (ICD10 code D47.4), during the three-year period from 1 July 2022 to 30 June 2025.

a. Section 40 exemption applied.

b. Section 40 exemption applied.

c. Based on the responses provided to questions 1, 3 and 4 for Myelofibrosis (ICD10 code D47.4), the UHB can confirm that twelve (12) of the patients were not treated with any other/unknown medication.

5. The UHB confirms that it is not currently participating in any clinical trials for the treatment of Myelofibrosis.